Kem製 Pharmaceuticals

Zevra Therapeutics, formerly known as KemPharm, is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases and CNS disorders. The company utilizes its proprietary Ligand Activated Therapy (LAT) platform to create prodrug versions of established molecules, aiming to improve their safety and efficacy profiles. Zevra's portfolio includes Azstarys, an FDA-approved treatment for ADHD, and arimoclomol, which is under regulatory review for Niemann-Pick disease type C. The company's pipeline also features candidates for idiopathic hypersomnia and stimulant use disorder, reflecting its commitment to addressing significant unmet medical needs.